Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.
The iShares Biotechnology ETF (IBB) fell 0.9%.
In corporate news, Arrowhead Pharmaceuticals (ARWR) shares jumped past 21% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.